Evidence map›Paper›PMID 33591478›Full record

ArticleMolecular imaging and biology2021

Intraoperative Detection of Micrometastases in Whole Excised Lymph Nodes Using Fluorescent Paired-Agent Imaging Principles: Identification of a Suitable Staining and Rinsing Protocol.

Chengyue Li, Veronica C Torres, Yusheng He, Xiaochun Xu, Yusairah Basheer, Georgia Papavasiliou, Kimberley S Samkoe, Jovan G Brankov, Kenneth M Tichauer

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chengyue LiBiomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA.
Veronica C TorresBiomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA.
Yusheng HeBiomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA.
Xiaochun XuThayer School of Engineering, Dartmouth College, Hanover, NH, 03755, USA.
Yusairah BasheerBiomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA.
Georgia PapavasiliouBiomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA.
Kimberley S SamkoeThayer School of Engineering, Dartmouth College, Hanover, NH, 03755, USA.
Jovan G BrankovElectrical and Computer Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA.
Kenneth M TichauerBiomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA. ktichaue@iit.edu.ORCID 0000-0003-1667-3026
Illinois Institute of Technology · USDartmouth College · USIIT Research Institute · US

Funding

Molecular Fluorescence-Guided Surgery PlatformR01CA167413 · NCI · DARTMOUTH COLLEGE · PI PAULSEN, KEITH D., SAMKOE, KIMBERLEY · 2013 to 2025
$5.7M
NCI NIH HHS R01 CA167413
6 · The paper itself

Abstract

purposeCorrectly identifying nodal status is recognized as a critical prognostic factor in many cancer types and is essential to guide adjuvant treatment. Currently, surgical removal of lymph nodes followed by pathological examination is commonly performed as a standard-of-care to detect node metastases. However, conventional pathology protocols are time-consuming, yet less than 1 % of lymph node volumes are examined, resulting in a 30-60 % rate of missed micrometastases (0.2-2 mm in size). PROCEDURES: This study presents a method to fluorescently stain excised lymph nodes using paired-agent molecular imaging principles, which entail co-administration of a molecular-targeted imaging agent with a suitable control (untargeted) agent, whereby any nonspecific retention of the targeted agent is accounted for by the signal from the control agent. Specifically, it was demonstrated that by dual-needle continuous infusion of either an antibody-based imaging agent pair (epidermal growth factor receptor (EGFR) targeted agent: IRDye-800CW labeled Cetuximab; control agent: IRDye-700DX-IgG) or an Affibody-based pair (EGFR targeted Affibody® agent: ABY-029; control agent IRDYe-700DX carboxylate) at 0.3 ml/min.

resultsThe results demonstrated the possibility to achieve >99 % sensitivity and > 95 % specificity for detection of a single micrometastasis (~0.2 mm diameter) in a whole lymph node within 22 min of tissue processing time.

conclusionThe detection capabilities offer substantial improvements over existing intraoperative lymph node biopsy methods (e.g., frozen pathology has a micrometastasis sensitivity <20 %).

Indexed as

BenzenesulfonatesIndolesBreast NeoplasmsCetuximabFemaleFluorescenceHumansLymph NodesNeoplasm MicrometastasisOptical ImagingStaining and LabelingTumor Cells, CulturedBenzenesulfonatesCetuximabIndolesIRDye 800CWIntraoperative imagingLymph nodeMicrometastasesPaired-agent

Identifiers

PMID33591478
OpenAlexW3130563578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.